- Conditions: Glaucoma; Ocular Hypertension
Interventions: Drug: 0.1% brimonidine tartrate and 0.01% bimatoprost; Drug: 0.01% bimatoprost and 0.2% hypromellose
Sponsors: Allergan; Allergan
Recruiting - verified January 2012 - Conditions: Open-angle Glaucoma; Ocular Hypertension
Intervention: Drug: Travoprost 0.004% without BAK containing Polyquad (PQ) preservative
Sponsors: Alcon Research; Alcon Research
Recruiting - verified January 2012 - Condition: Glaucoma
Interventions: Drug: bimatoprost ophthalmic solution formulation A, bimatoprost vehicle; Drug: timolol ophthalmic solution
Sponsors: Allergan; Allergan
Recruiting - verified November 2011 - Condition: Glaucoma
Intervention: Drug: Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination ophthalmic solution (DUOTRAV)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified April 2012 - Condition: Open-Angle Glaucoma
Interventions: Drug: bimatoprost ophthalmic formulation A, bimatoprost ophthalmic solution 0.03%; Drug: bimatoprost ophthalmic formulation B, bimatoprost ophthalmic solution 0.03%; Drug: bimatoprost ophthalmic formulation C, bimatoprost ophthalmic solution 0.03%
Sponsors: Allergan; Allergan
Recruiting - verified December 2011 - Conditions: Eyelash Hypotrichosis; Alopecia Areata
Interventions: Drug: bimatoprost ophthalmic solution 0.03%; Drug: Vehicle Sterile Solution
Sponsors: Allergan; Allergan
Recruiting - verified November 2011 - Conditions: Alopecia; Breast Cancer
Interventions: Drug: bimatoprost ophthalmic solution; Drug: placebo
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
 |
Bimatoprost Clinical Trials |
